Core Viewpoint - The article highlights the offerings of the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and live chat features for investors [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, is a private investor with a background in Applied Science, focusing on generating long-term value in the healthcare sector [2]. - The service aims to assist healthcare investors in making informed decisions through comprehensive analysis and news reports [2].

Core Viewpoint - Inhibrx has experienced a significant stock rally of over 150% following positive topline results from its registrational trial of Ozekibart (INBRX-109), but this movement raises structural risks when analyzed through the Adhishthana framework [1][8]. Group 1: Monthly Structure Analysis - Inhibrx is currently in Phase 2 of its 18-phase Adhishthana cycle, which consists of two segments: the Sankhya period characterized by consolidation or corrective behavior, and the Buddhi period known for strong upside momentum [2]. - The stock is navigating the early Sankhya portion of Phase 2, having delivered a sharp upside move instead of the expected consolidation or correction, indicating a deviation from the anticipated structure [3][6]. - Historically, premature strength during the Sankhya phase often leads to instability later in the cycle, as seen in the case of Lamb Weston, which faced a collapse of over 60% after a similar premature rally [5]. Group 2: Investor Outlook - The current rally of Inhibrx is unfolding at an unfavorable point in the cycle, suggesting that the medium-term outlook warrants caution for investors [7]. - Investors who established positions prior to the Ozekibart announcement may continue to hold, but should be aware of the structural risks associated with the current rally, which may not be sustainable [8].

Core Insights - Inhibrx Biosciences, Inc. announced updates on its clinical trials for INBRX-106 and ozekibart, focusing on oncology therapeutics [1] INBRX-106 Clinical Trials - The Phase 2 portion of the INBRX-106 trial has recruited 46 out of 60 patients, with expected completion of enrollment in Q1 2026 [2] - The trial targets patients with unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) who have not received prior systemic therapy and have tumor PD-L1 CPS expression ≥ 20 [2] - Primary endpoint is overall response rate, with secondary endpoints including duration of response, progression-free survival, and safety [2] - Data maturity for HNSCC and NSCLC trials is anticipated in H2 2026 to assess the efficacy of INBRX-106 in combination with Keytruda [4] Ozekibart Clinical Trials - Enrollment for the Phase 1/2 trial of ozekibart in combination with FOLFIRI for advanced colorectal cancer has been completed with 44 patients [5] - Ozekibart showed good tolerability and durable responses, with progression-free survival data expected in Q2 2026 [5] - The trial for ozekibart in combination with irinotecan and temozolomide for Ewing sarcoma is expected to complete enrollment in Q2 2026, with plans to discuss accelerated approval with the FDA in H2 2026 if trends continue [6] Product Descriptions - INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40, currently being investigated for HNSCC and NSCLC [7] - Ozekibart is a tetravalent DR5 agonist antibody designed to induce tumor-biased cell death, with a BLA filing expected in early Q2 2026 [8] Company Overview - Inhibrx Biosciences focuses on developing a pipeline of novel biologic therapeutic candidates using advanced protein engineering methods [9]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Elpiscience Biopharmaceuticals, Inc. 科望醫藥集團 （「本公司」） （根據開曼群島法律註冊成立之有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、其獨家保薦人、獨家保薦人兼整體協調人、顧問或包銷團成員表 示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長登記 的本公司招股章程作出投資決定，招股章程的文本於發售期內將可供公眾查閱。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本 文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充 ...

Core Insights - Inhibrx Biosciences, Inc. reported financial results for Q3 2025, highlighting the completion of the sale of INBRX-101 to Sanofi S.A. and the spin-off of Inhibrx as a standalone entity [1][4] - The company has two ongoing clinical programs, with positive topline results from the registrational trial of ozekibart (INBRX-109) in chondrosarcoma [2][9] - Inhibrx plans to submit a biologics license application to the U.S. FDA in Q2 2026 [6] Recent Corporate Highlights - On October 23, 2025, Inhibrx announced positive topline results from its trial of ozekibart in chondrosarcoma, demonstrating significant improvement in median progression-free survival compared to placebo [2][6] - Interim data from expansion cohorts in colorectal cancer and Ewing sarcoma show high response and disease control rates in heavily pretreated patients [6] Financial Results - As of September 30, 2025, Inhibrx had cash and cash equivalents of $153.1 million, down from $186.6 million as of June 30, 2025 [6] - Research and development expenses for Q3 2025 were $28.5 million, a decrease from $38.9 million in Q3 2024, primarily due to reduced process development and manufacturing activities [6][7] - General and administrative expenses were $5.3 million in Q3 2025, down from $7.9 million in Q3 2024, attributed to decreased legal and personnel-related expenses [6][7] - The net loss for Q3 2025 was $35.3 million, or $2.28 per share, compared to a net loss of $43.9 million, or $2.84 per share, in Q3 2024 [6][7] Summary of Financial Performance - Total revenue for Q3 2025 was $1.3 million, compared to $0.1 million in Q3 2024 [7] - Total operating expenses for Q3 2025 were $33.8 million, down from $46.8 million in Q3 2024 [7] - The company reported total liabilities of $140.6 million as of September 30, 2025, with stockholders' equity at $36.8 million [7]

Core Insights - Inhibrx Biosciences, Inc. is set to present clinical data on its DR5 Agonist at multiple upcoming scientific conferences, highlighting its focus on novel biologic therapeutic candidates [1][2][3] Conference Presentations - The company will present at the 21st Annual Industry/Academia Precision Oncology & Radmed Symposium on November 5, 2025, discussing DR5 Agonist clinical data in various cancers [1] - At the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting from November 12-15, 2025, Inhibrx will present results from the Phase 2 ChonDRAgon Study on ozekibart (INBRX-109) in conventional chondrosarcoma [2] - The Society for NeuroOncology (SNO) 2025 Annual Meeting from November 19-23, 2025, will feature a poster presentation on the anti-tumor activity of ozekibart in GBM models [3] Company Overview - Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, utilizing diverse protein engineering methods [4] - The company was incorporated in January 2024 and has a current clinical pipeline that includes ozekibart and INBRX-106, both employing multivalent formats for optimized agonist function [4]

Core Viewpoint - The analysis of Inhibrx Biosciences (NASDAQ: INBX) reflects a shift from initial optimism at a share price of $15 to a more cautious outlook as the price fluctuated, highlighting the volatility in biotech investments [1]. Company Analysis - Inhibrx Biosciences has been under scrutiny due to its share price movements, which have influenced investor sentiment and expectations [1]. - The author possesses a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, indicating a strong foundation for evaluating the company's potential [1]. Industry Insights - The biotech sector is characterized by significant risks and opportunities, necessitating thorough due diligence to avoid potential pitfalls in investment [1].

Core Insights - The article discusses Inhibrx Biosciences, Inc. (NASDAQ: INBX) and its recent developments, particularly following the sale of INBRX-101 to Sanofi [2]. Group 1: Company Overview - Inhibrx Biosciences is highlighted for its continued advancements in the biotech sector despite the recent sale of a key asset [2]. Group 2: Market Position - The author operates a service called Biotech Analysis Central, which provides in-depth analysis of various pharmaceutical companies, indicating a focus on small and mid-cap stocks [2].

Core Insights - The article discusses Inhibrx Biosciences, Inc. (NASDAQ: INBX) and its recent developments, particularly following the sale of INBRX-101 to Sanofi [2]. Company Overview - Inhibrx Biosciences is highlighted for its continued advancement in the biotech sector, indicating a positive trajectory despite the sale of a key asset [2]. Investment Analysis - The author operates a service called Biotech Analysis Central, which provides in-depth analysis of various pharmaceutical companies, including a model portfolio of small and mid-cap stocks [2].

Core Insights - Inhibrx Biosciences Inc. shares experienced a significant increase of 75.95% in after-hours trading, closing at $49.90 after a regular trading session where the stock fell by 10.03% to $28.36 [1][6] Study Results - The company announced positive topline results from the ChonDRAgon study, a Phase 2 trial evaluating ozekibart (INBRX-109) for patients with advanced or metastatic, unresectable chondrosarcoma [2][4] - The study, involving 206 patients, met its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival (PFS) [3] - Ozekibart reduced the risk of disease progression or death by 52% compared to placebo, with a median PFS of 5.52 months versus 2.66 months for placebo [3] Additional Data - Ozekibart is noted as the first experimental therapy to show a progression-free survival benefit in a randomized trial for chondrosarcoma, a cancer lacking approved systemic treatments [4] - Expansion cohort results indicated a 23% overall response rate for ozekibart combined with FOLFIRI in late-line colorectal cancer patients, and a 64% overall response rate when combined with irinotecan and temozolomide in refractory Ewing sarcoma patients [5] Stock Performance - Inhibrx's stock has increased by 84.16% year-to-date, although it has fallen 25.8% from its year-to-date high of $38.22 [6] - The stock has a 52-week range of $10.80 to $39.27 and a market capitalization of $410.81 million [6]